ETS2 and inflammatory bowel disease: We showed that drugs which target the MAPK pathway – which activates ETS-family transcription factors – can downregulate the ETS2 transcriptional programme in silico (Stathias et al., 2020) and confirmed that one such class, MEK1/2 inhibitors, which are already used to treat non-inflammatory conditions (de Blank et al., 2022), could reduce pathological inflammation and the secretion of key pro-inflammatory cytokines in IBD biopsies.